Moderna and carisma establish collaboration to develop in vivo engineered chimeric antigen receptor monocytes (car-m) for oncology

Cambridge, mass. and philadelphia, jan. 10, 2022 /prnewswire/ -- moderna inc. (nasdaq: mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and carisma therapeutics inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that the two companies have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (car-m) therapeutics for the treatment of cancer.
MRNA Ratings Summary
MRNA Quant Ranking